Once-daily nebivolol 5mg does not reduce airway patency in patients with chronic obstructive pulmonary disease and arterial hypertension: A placebo-controlled crossover study

Clinical Drug Investigation

Volumn 22, Issue 6, 2002, Pages 361-367

  Dal Negro, R W ^a   Tognella, S ^a   Pomari, C ^a  

^a Orlandi General Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NEBIVOLOL; NITRIC OXIDE; PLACEBO; SALBUTAMOL;

ADULT; AGED; AIRWAY OBSTRUCTION; AIRWAY RESISTANCE; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE MONITORING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; HEART RATE; HUMAN; HYPERTENSION; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 0036286124     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222060-00003     Document Type: Article

References (28)

1. β-adrenergic blocking agents in bronchospastic diseases: A therapeutic dilemma
2. Effect of nebivolol, atenolol, and propranolol on airway •-adrenergic responsiveness in normal subject
3. Effect of propranolol on ventilatory function
4. Comparison of respiratory and cardiovascular effects of isoproterenol, propranolol and practolol in asthmatic and normal subjects
5. The beta adrenergic theory of the atopic abnormality in bronchial asthma
6. The effect of beta-adrenergic blockade on bronchial sensitivity to acetyl-beta-methacholine in normal and allergic rhinitis subjects
7. Nebivolol is devoid of intrinsic sympathomimetic activity
8. Nebivolol in the management of essential hypertension: A review
9. Pharmacology of nebivolol
10. Nebivolol: A third-generation beta-blocker that augments vascular nitric oxide release: Endothelial beta(2)-adrenergic receptor-mediated nitric oxide production
11. Beta-adrenergic blocking agents: Past, present and future perspectives
12. Optimal assessment and management of chronic obstructive pulmonary disease (COPD)
13. Standardized lung function testing
14. Exhaled and nasal nitric oxide measurements: Recommendations
15. Adverse effects of β-adrenergic receptor blocking drugs on respiratory function
16. Ventilatory effects of long-term treatment with pindolol and metoprolol in hypertensive patients with chronic obstructive lung disease
17. Safety and efficacy of celiprolol in hypertensive patients with chronic obstructive lung disease
18. Nitric oxide mediated venodilator effects of nebivolol
19. Nebivolol induces endothelium-dependent relaxations of canine arteries
20. Nebivolol vasodilates human forearm vasculature: Evidence of an L-arginine/NO-dependent mechanism
21. Exhaled nitric oxide and induced sputum analysis as markers of airway inflammation in subjects with COPD
22. Beta-adrenoceptor blockade and pulmonary function in patients suffering from chronic obstructive lung disease
23. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease
24. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris
25. Effect of different beta-receptor blockers on the respiratory function of patients with chronic obstructive pulmonary disease and arterial hypertension
26. Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension
27. Comparison of the effects of single oral doses of nebivolol and celiprolol an airways in patients with mild asthma
28. Pharmacokinetics of the effect of nebivolol 5mg on airway patency in patients with mild to moderate bronchial asthma and arterial hypertension